Pearls and pitfalls of premium IOLs
Three physicians discuss how they help patients on their journey as they seek out a toric or presbyopia-correcting IOL.
Browse articles from EyeWorld.org related to IOLs. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
Three physicians discuss how they help patients on their journey as they seek out a toric or presbyopia-correcting IOL.
When a patient comes in prior to cataract surgery, it’s important to do a careful evaluation to see what conditions they might have and how this could impact IOL selection. Two physicians discussed conditions to be aware of when considering presbyopia-correcting IOLs and how to talk to patients prior to surgery.
Enhanced monofocal and “ringless” EDOFs are a couple of the names floating around for a newer type of IOL designed to extend depth of focus while maintaining, as much as possible, the quality of distance vision provided by a monofocal IOL. This article explores physician experience with these new IOL options.
Glaucoma should not necessarily be an immediate contraindication to premium cataract surgery technologies, such as toric and presbyopia-correcting IOLs and FLACS. Reay Brown, MD, Paul Harasymowycz, MD, and Joey Hsia, MD, said there are situations where these IOL technologies are suited for glaucoma patients, but the decision to offer them is not as straightforward.
➤ FDA approves spheric, monofocal IOL ➤ Phase 2/3 study of gene therapy for retinitis pigmentosa does not meet primary endpoint ➤ Study: Compounded cyclosporine drop significantly improves OSDI scores ➤ Subretinal injector receives FDA pre-market approval ➤ Three companies form strategic alliance to develop cell therapies ➤ ASCRS events
➤ FDA approves new presbyopia-correcting IOL ➤ New way to evaluate sickle cell retinopathy ➤ Positive Phase 2a data on novel, topical dry eye disease drug candidate ➤ Second Phase 3 trial initiated for Demodex blepharitis treatment ➤ Large-scale, randomized controlled trial replicated with real-world data set ➤ ASCRS events
➤ FDA approves enhanced monovision IOL ➤ Report: Demand for refractive surgery up amid pandemic ➤ Study: Antifibrotic activity of rho-kinase inhibitors ➤ Companies partner to explore nanoparticle applications for ophthalmic therapies ➤ ASCRS Journal Club on April 8
➤ FDA approves elements of artificial vision system for blind patients ➤ Expanded indication for MIGS device ➤ 5-year pivotal trial data for MIGS device ➤ Topline results from Phase 2 study of investigational MGD treatment
New optical qualities, new materials, preloaded inserters, and the possibility of accommodative abilities: There has been quite a bit of movement in IOL innovations, some of which are available in the U.S., while others are still on the horizon.
➤ PMA submitted to FDA for small-aperture IOL ➤ Preclinical results for new class of non-prostaglandin analogs for IOP lowering ➤ A Phase 2 clinical trial begins enrollment for topical presbyopia-correcting drop ➤ Home OCT technology used in clinical trial to reduce participant visits to offices ➤ ASCRS Journal Club on March 11